SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Fresenius Medical Care AG & Co. KGaA (FMS) trades at a trailing P/E of 11.7, forward P/E of 11.2. Trailing earnings yield is 8.58%, forward earnings yield 8.90%. PEG 0.14 (Peter Lynch undervalued ≤1.0). Graham Number is $31.01.
Criteria proven by this page:
- VALUE (83/100, Pass) — P/E is below market average (11.7); PEG ≤ 1.0 — Peter Lynch undervalued (0.14); analyst target implies upside (+20.6%); earnings yield beats bond yields (8.58%).
- Forward P/E 11.2 (down from trailing 11.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.14 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 8.58% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.90% as earnings recover.
- Analyst consensus target $28.00 (+20.6% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 68/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
83/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — FMS
Valuation Multiples
P/E (TTM)11.7
Forward P/E11.2
PEG Ratio0.14
Forward PEG0.49
P/B Ratio0.80
P/S Ratio0.59
EV/EBITDA6.3
Per Share Data
EPS (TTM)$1.71
Forward EPS (Est.)$2.06
Book Value / Share$24.98
Revenue / Share$34.33
FCF / Share$3.06
Yields & Fair Value
Earnings Yield8.58%
Forward Earnings Yield8.90%
Dividend Yield3.38%
Graham Number$31.01
SharesGrow IV$92.95 (+300.5%)
Analyst Target$28.00 (+20.6%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
20.8 |
1.09 |
2.46 |
1.44 |
1.07% |
| 2017 |
21.0 |
1.82 |
2.73 |
1.51 |
1.10% |
| 2018 |
8.8 |
0.16 |
1.48 |
1.05 |
1.87% |
| 2019 |
24.3 |
-0.42 |
2.44 |
1.67 |
1.22% |
| 2020 |
25.9 |
-8.75 |
2.69 |
1.69 |
1.16% |
| 2021 |
34.5 |
-0.94 |
2.63 |
1.90 |
1.17% |
| 2022 |
26.6 |
-0.87 |
1.28 |
0.92 |
2.21% |
| 2023 |
22.6 |
0.47 |
0.83 |
0.58 |
2.91% |
| 2024 |
23.9 |
3.12 |
0.88 |
0.66 |
2.72% |
| 2025 |
12.1 |
0.14 |
0.83 |
0.60 |
3.44% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.87 |
$17.03B |
$1.18B |
6.9% |
| 2017 |
$2.08 |
$17.78B |
$1.28B |
7.2% |
| 2018 |
$3.23 |
$16.55B |
$1.98B |
12% |
| 2019 |
$1.98 |
$17.48B |
$1.2B |
6.9% |
| 2020 |
$1.98 |
$17.86B |
$1.16B |
6.5% |
| 2021 |
$1.66 |
$17.62B |
$969.31M |
5.5% |
| 2022 |
$1.15 |
$19.4B |
$673.41M |
3.5% |
| 2023 |
$0.85 |
$19.45B |
$499M |
2.6% |
| 2024 |
$0.92 |
$19.34B |
$537.91M |
2.8% |
| 2025 |
$1.68 |
$19.63B |
$978M |
5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.06 |
$1.76 – $2.31 |
$19.64B |
$19.58B – $19.68B |
6 |
| 2027 |
$2.24 |
$2.01 – $2.64 |
$20.29B |
$20.02B – $20.7B |
5 |
| 2028 |
$2.53 |
$2.48 – $2.66 |
$20.99B |
$20.62B – $21.82B |
2 |
| 2029 |
$2.95 |
$2.89 – $3.11 |
$21.91B |
$21.51B – $22.77B |
1 |
| 2030 |
$3.26 |
$3.19 – $3.43 |
$22.84B |
$22.44B – $23.75B |
1 |
